Core Alternative Capital’s TG Therapeutics TGTX Stock Holding History

Core Alternative Capital’s Portfolio TGTX Stock Details TGTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-180	Closed	-$5.98K	–	206
2026 Q1	$5.98K	Hold	180	–	–	﹤0.01%	193
2025 Q4	$5.37K	Hold	180	–	–	﹤0.01%	195
2025 Q3	$6.5K	Hold	180	–	–	﹤0.01%	191
2025 Q2	$6.48K	Hold	180	–	–	﹤0.01%	190
2025 Q1	$7.1K	Hold	180	–	–	﹤0.01%	189
2024 Q4	$5.42K	Buy	+180	New	+$5.17K	﹤0.01%	225

Other funds holding TGTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Core Alternative Capital's TGTX Position: Q2 2026 in Review

Core Alternative Capital sold out of TG Therapeutics (TGTX) in Q2 2026, closing a stake of 180 shares — an estimated $5.98K sold.

Core Alternative Capital first reported a position in TGTX in Q4 2024 and held it in 6 quarters. The position peaked at $7.1K in Q1 2025. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

Core Alternative Capital reported no remaining TG Therapeutics position as of Q2 2026 after selling out during the quarter.
Core Alternative Capital sold 180 TG Therapeutics shares in Q2 2026, an estimated $5.98K.
Core Alternative Capital first reported a position in TG Therapeutics in Q4 2024 and held it in 6 quarters.
Core Alternative Capital's TG Therapeutics position peaked at $7.1K in Q1 2025.
429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Core Alternative Capital's 13F filing for Q2 2026, filed 14 Aug 2026.